The α-MSH analog setmelanotide is approved for some homozygous monogenic mutations (LEPR, MC4R, POMC, PCSK1) in the leptin–melanocortin pathway to treat severe obesity and is being studied for heterozygous mutations as well [101,102]. The gene discussed is LEP; the disease is obesity due to melanocortin 4 receptor deficiency.